19 November 2019 5 Min Read
Crispr surges 21% on results of in-human study using gene-editing tool
Crispr is also studying medicines in both solid and blood cancers and is in the early stages of developing treatments for diabetes and cystic fibrosis
Subscribe to our website to read this article and support quality journalism.
If you’ve already subscribed, simply sign in.
Subscribe Sign In